In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings ...
MASON, Ohio, December 23, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management ...
JPMorgan analyst Lilia-Celine Lozada assumed coverage of AtriCure (ATRC) with an Overweight rating and $40 price target With numbers reset and competitive headwinds not materializing as feared ...
Hosted on MSN4mon
AtriCure's Shares Likely to Benefit From New AtriClip Device SalesIndustry Prospects Favoring AtriCure Per a report by Grand View Research, the global atrial fibrillation market size was estimated to be $22.4 billion in 2022 and is expected to witness a growth ...
AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The business had revenue of $115.91 million for the quarter, compared to analysts’ expectations of $112.23 ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management ...
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback